Predictors of adherence, bivariate analysis
| Factors | n | OR (95% CI) | P value |
| Sociodemographic factors | |||
| Female sex | 171 | 0.90 (0.44 to 1.85) | 0.775 |
| Age (per year increase) | 171 | 0.98 (0.96 to 1.01) | 0.270 |
| Level of education | 165 | ||
| Primary | 1 | ||
| Secondary | 1.66 (0.80 to 3.42) | 0.170 | |
| College | 1.37 (0.37 to 5.10) | 0.634 | |
| University | 0.86 (0.33 to 2.19) | 0.747 | |
| Economic difficulties | 167 | 0.93 (0.45 to 1.90) | 0.840 |
| Living in a couple | 167 | 1.38 (0.67 to 2.84) | 0.381 |
| Smoking | 165 | ||
| Never smoker | 1 | ||
| Ex-smoker (>1 year) | 0.65 (0.32 to 1.31) | 0.225 | |
| Active smoker | 0.75 (0.32 to 1.76) | 0.507 | |
| Clinical factors | |||
| Swelling joints | 171 | 0.96 (0.81 to 1.13) | 0.606 |
| Painful joints | 171 | 0.98 (0.89 to 1.08) | 0.686 |
| Erythrocyte sedimentation rate (mm/hour) | 149 | 1.02 (1.00 to 1.04) | 0.098 |
| C reactive protein (mg/dL) | 154 | 1.34 (0.79 to 2.29) | 0.274 |
| Patient Global Assessment (0–10) | 169 | 1.04 (0.94 to 1.15) | 0.451 |
| Physician Global Assessment (0–10) | 171 | 0.93 (0.82 to 1.04) | 0.214 |
| DAS-28 | 147 | 1.17 (0.85 to 1.60) | 0.329 |
| RAID | 167 | 0.99 (0.89 to 1.11) | 0.918 |
| Comorbidities (number) | 171 | 1.02 (0.79 to 1.33) | 0.852 |
| Time of evolution (years) | 156 | 1.00 (0.96 to .03) | 0.912 |
| Treatment-related factors | |||
| Current treatment | 171 | ||
| First-line csDMARD | 1 | ||
| Second-line csDMARD | 3.13 (1.43 to 6.85) | 0.004 | |
| bDMARD/tsDMARD | 2.39 (1.13 to 5.03) | 0.022 | |
| Glucocorticoids | 171 | 1.11 (0.59 to 2.08) | 0.754 |
| NSAIDs | 171 | 2.41 (1.01 to 5.75) | 0.046 |
| In-hospital treatment | 170 | 2.14 (1.14 to 4.01) | 0.017 |
| Treatment agreed | 167 | 2.88 (1.26 to 6.58) | 0.012 |
| Prior adverse events (patient-reported) | 170 | ||
| No | 1 | ||
| Yes, but tolerable | 1.07 (0.42 to 2.67) | 0.891 | |
| Yes, with changes | 1.89 (0.96 to 3.71) | 0.065 | |
| Prior serious adverse events (from eCR) | 171 | 1.21 (0.52 to 2.84) | 0.654 |
| Concomitant treatments | 171 | 1.03 (0.81 to 1.31) | 0.796 |
| Administration is felt easy. | 171 | 0.70 (0.20 to 2.44) | 0.580 |
| Fear of medicine | 169 | 0.81 (0.35 to 1.87) | 0.627 |
| Patient–doctor relationship | |||
| Accessibility to rheumatologist (0–10) | 167 | 1.12 (0.91 to 1.38) | 0.278 |
| Trust in the rheumatologist (0–10) | 165 | 1.14 (0.90 to 1.44) | 0.289 |
| Patient trust in doctor (physician, 0–10) | 171 | 1.71 (1.25 to 2.33) | 0.001 |
| Patient trust in treatment (physician, 0–10) | 169 | 1.22 (0.97 to 1.54) | 0.095 |
| Time of visit | 165 | ||
| Very short | 1 | ||
| Suitable | 1.48 (0.20 to 10.7) | 0.701 | |
| Very long | 4.0 (0.211 to 75.6) | 0.355 | |
| Information is felt consistent. | 168 | 0.73 (0.13 to 4.09) | 0.718 |
| Adequacy of information (patient, 0–10) | |||
| Efficacy | 170 | 1.25 (1.08 to 1.45) | 0.002 |
| Toxicity | 168 | 1.06 (0.95 to 1.17) | 0.281 |
| Practical aspects | 169 | 1.14 (0.96 to 1.36) | 0.137 |
| Adaptation to needs | 166 | 1.35 (1.14 to 1.59) | 0.001 |
| Adequacy of information (physician, 0–10) | |||
| Efficacy | 171 | 1.72 (1.26 to 2.35) | 0.001 |
| Toxicity | 171 | 1.44 (1.10 to 1.87) | 0.007 |
| Practical aspects | 170 | 1.40 (1.07 to 1.84) | 0.014 |
| Adaptation to needs | 171 | 1.34 (1.02 to 1.75) | 0.033 |
| Access to health professionals if there are doubts | 167 | 4.27 (1.09 to 16.7) | 0.037 |
| Psychosocial factors | |||
| BMQ score | |||
| Need (0–25) | 170 | 1.03 (0.95 to 1.11) | 0.487 |
| Concern/damage (0–25) | 170 | 0.97 (0.91 to 1.03) | 0.318 |
| Feeling privileged by the medication | 168 | 3.26 (1.45 to 7.37) | 0.004 |
| Anxiety/depression | 163 | 0.73 (0.33 to 1.63) | 0.447 |
| Family/social support (0–10) | 165 | 1.09 (0.93 to 1.28) | 0.284 |
| Time to measure adherence (months) | 171 | 0.064 | |
| <6 | 1 | ||
| ≥6 | 1.98 (0.96 to 4.07) |
bDMARD, biological disease-modifying antirheumatic drug; BMQ, Beliefs about Medicines Questionnaire; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying anti-rheumatic drug (c, conventional; eCR, electronic clinical records; NSAID, non-steroidal anti-inflammatory drug; RAID, Rheumatoid Arthritis Impact of Disease Index.